News | February 03, 2015

Study Shows Grafting Surgery Provides Better Value than Angioplasty

Research examines costs and quality of life benefits of two common heart procedures

ASCERT, coronary bypass graft surgery, angioplasty, quality of life, value

February 3, 2015 — Coronary bypass graft surgery commonly used to treat patients with coronary heart disease results in improved quality of life but also costs more than another often-used less invasive technique, Christiana Care Health System researchers reported in January in the Journal of the American College of Cardiology.

Known as the ASCERT (American College of Cardiology Foundation–The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies) study, this research represents the first of its kind nationwide to evaluate and compare hundreds of thousands of clinical and claims data to determine both the survival benefit and overall costs of coronary artery bypass graft compared to percutaneous coronary intervention, another common surgical procedure that is also referred to as angioplasty.

The study found that patients who underwent bypass graft surgery lived longer and were able to function better and had less additional procedures than those treated with angioplasty. Researchers drew their conclusions by analyzing a widely-accepted metric known as quality-adjusted life-years.

“While other studies have compared the costs of the two types of treatment, we wanted to probe deeper to understand the value of these procedures to patients,” said Zugui Zhang, Ph.D., a senior biostatistician and scholar at Christiana Care’s Value Institute, and lead author in the study. “Although the grafting procedure costs more, we also found that patients who underwent that procedure lived longer and had fewer additional procedures.”

Over a four-year period, the study looked at people 65 years or older with coronary heart disease in two or three of their heart vessels.

In addition to the quality of life metrics, researchers found the grafting procedure also resulted in higher costs per patient than angioplasty in three areas:

  • Hospitalization was on average $10,670 more.
  • Clinical care after the surgery was on average $8,145 more.
  • Lifetime projected costs after the surgery were on average $11,575 more.

 

“Coronary heart disease affects so many of our neighbors, so our hope is to provide patients and their families with knowledge so they can make informed decisions on their health care,” Zhang said. “Through this study, we have found that coronary artery bypass grafts provide a reasonably better value to patients when compared to angioplasties.”

For more information: www.christianacare.org

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init